Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for SLN
| Stock Name | Silence Therapeutics PLC |
| Ticker | SLN(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US82686Q1013 |
| LEI | 213800SSURRJBX85SQ91 |
Show aggregate SLN holdings
News associated with SLN
- Silence Therapeutics (NASDAQ:SLN) Given “Buy” Rating at Chardan Capital
- Chardan Capital reissued their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a report issued on Friday,Benzinga reports. They currently have a $35.00 price objective on the stock. Several other equities research analysts have also recently commented on the company. The Goldman Sachs Group lowered their price target on Silence Therapeutics […] - 2025-08-11 02:24:46
- Wall Street Zen Downgrades Silence Therapeutics (NASDAQ:SLN) to Sell
- Silence Therapeutics (NASDAQ:SLN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday. A number of other equities research analysts also recently issued reports on the company. The Goldman Sachs Group lowered their price objective on Silence […] - 2025-07-14 03:30:48
- Contrasting Silence Therapeutics (NASDAQ:SLN) and TransCode Therapeutics (NASDAQ:RNAZ)
- TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) and Silence Therapeutics (NASDAQ:SLN – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of recent […] - 2025-06-24 02:36:56
- Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
- Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months. - 2025-06-23 10:09:00
- Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Stock Holdings Lowered by SG Americas Securities LLC
- SG Americas Securities LLC lowered its position in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Free Report) by 2.9% in the 1st quarter, Holdings Channel reports. The fund owned 308,289 shares of the company’s stock after selling 9,339 shares during the period. SG Americas Securities LLC’s holdings in Silence Therapeutics were worth $869,000 […] - 2025-06-19 04:48:52
- Chardan Capital Reaffirms Buy Rating for Silence Therapeutics (NASDAQ:SLN)
- Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a report issued on Friday,Benzinga reports. Chardan Capital currently has a $35.00 price target on the stock. Several other brokerages have also recently issued reports on SLN. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective […] - 2025-06-16 02:30:47
- Silence Therapeutics (NASDAQ:SLN) Upgraded at Wall Street Zen
- Silence Therapeutics (NASDAQ:SLN – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday. SLN has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares […] - 2025-06-16 02:30:47
- Two Sigma Investments LP Lowers Position in Silence Therapeutics plc (NASDAQ:SLN)
- Two Sigma Investments LP lowered its holdings in Silence Therapeutics plc (NASDAQ:SLN – Free Report) by 16.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 142,052 shares of the company’s stock after selling 27,340 shares during the period. Two Sigma […] - 2025-06-06 04:42:48
- Two Sigma Advisers LP Grows Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)
- Two Sigma Advisers LP grew its holdings in Silence Therapeutics plc (NASDAQ:SLN – Free Report) by 18.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,800 shares of the company’s stock after purchasing an additional 15,500 shares during the quarter. Two […] - 2025-06-03 05:00:50
- The Goldman Sachs Group Has Lowered Expectations for Silence Therapeutics (NASDAQ:SLN) Stock Price
- Silence Therapeutics (NASDAQ:SLN – Free Report) had its price target cut by The Goldman Sachs Group from $4.00 to $3.00 in a report issued on Friday,Benzinga reports. They currently have a sell rating on the stock. SLN has been the topic of a number of other research reports. Morgan Stanley dropped their price objective on […] - 2025-05-12 02:44:44
- JPMorgan Chase & Co. Invests $26,000 in Silence Therapeutics plc (NASDAQ:SLN)
- JPMorgan Chase & Co. purchased a new stake in Silence Therapeutics plc (NASDAQ:SLN – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm purchased 3,793 shares of the company’s stock, valued at approximately $26,000. Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing […] - 2025-05-09 04:16:48
- Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) Price Target at $40.67
- Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among […] - 2025-04-21 02:14:47
- Trexquant Investment LP Buys Shares of 63,663 Silence Therapeutics plc (NASDAQ:SLN)
- Trexquant Investment LP purchased a new position in Silence Therapeutics plc (NASDAQ:SLN – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 63,663 shares of the company’s stock, valued at approximately $438,000. Trexquant Investment LP owned 0.21% of Silence Therapeutics at […] - 2025-04-13 05:31:04
- Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $4.00 at The Goldman Sachs Group
- Silence Therapeutics (NASDAQ:SLN – Free Report) had its price target trimmed by The Goldman Sachs Group from $6.00 to $4.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a sell rating on the stock. Several other equities research analysts also recently weighed in on SLN. BMO Capital Markets reissued an “outperform” rating […] - 2025-03-05 08:07:39
- Silence Therapeutics (NASDAQ:SLN) Given New $25.00 Price Target at BMO Capital Markets
- Silence Therapeutics (NASDAQ:SLN – Free Report) had its price objective reduced by BMO Capital Markets from $67.00 to $25.00 in a report issued on Tuesday,Benzinga reports. They currently have an outperform rating on the stock. Several other brokerages have also recently weighed in on SLN. Chardan Capital reissued a “buy” rating and set a $55.00 […] - 2025-03-05 08:07:33
- Analysts Set Silence Therapeutics plc (NASDAQ:SLN) PT at $45.00
- Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year […] - 2025-03-04 04:47:02
- The Goldman Sachs Group Initiates Coverage on Silence Therapeutics (NASDAQ:SLN)
- Stock analysts at The Goldman Sachs Group began coverage on shares of Silence Therapeutics (NASDAQ:SLN – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “sell” rating and a $6.00 price target on the stock. The Goldman Sachs Group’s price objective would indicate […] - 2025-02-13 06:46:49
- China Universal Asset Management Co. Ltd. Invests $69,000 in Silence Therapeutics plc (NASDAQ:SLN)
- China Universal Asset Management Co. Ltd. bought a new stake in shares of Silence Therapeutics plc (NASDAQ:SLN – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 9,963 shares of the company’s stock, valued at approximately $69,000. Several other hedge funds have also modified their holdings […] - 2025-02-04 06:53:04
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) SLN holdings
| Date | Number of SLN Shares Held | Base Market Value of SLN Shares | Local Market Value of SLN Shares | Change in SLN Shares Held | Change in SLN Base Value | Current Price per SLN Share Held | Previous Price per SLN Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of SLN by Blackrock for IE00BYXG2H39
Show aggregate share trades of SLN| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-06 | BUY | 273 | 5.190 | 5.200 | 5.199 | USD 1,419 | 4.89 |
| 2025-10-03 | BUY | 637 | 5.000 | 5.260 | 5.234 | USD 3,334 | 4.89 |
| 2025-10-02 | BUY | 91 | 5.200 | 5.290 | 5.281 | USD 481 | 4.88 |
| 2025-09-30 | BUY | 180 | 5.190 | 5.610 | 5.568 | USD 1,002 | 4.88 |
| 2025-09-26 | BUY | 182 | 5.540 | 5.550 | 5.549 | USD 1,010 | 4.87 |
| 2025-09-25 | BUY | 182 | 5.000 | 5.240 | 5.216 | USD 949 | 4.87 |
| 2025-09-24 | BUY | 1 | 5.140 | 5.303 | 5.287 | USD 5 | 4.87 |
| 2025-09-18 | BUY | 90 | 5.030 | 5.185 | 5.169 | USD 465 | 4.87 |
| 2025-09-17 | BUY | 273 | 5.010 | 5.270 | 5.244 | USD 1,432 | 4.87 |
| 2025-09-11 | SELL | -91 | 4.880 | 5.250 | 5.213 | USD -474 | 4.87  Loss of -31 on sale |
| 2025-09-10 | BUY | 182 | 4.810 | 5.360 | 5.305 | USD 966 | 4.87 |
| 2025-09-05 | SELL | -91 | 5.690 | 5.690 | 5.690 | USD -518 | 4.86 Loss of -75 on sale |
| 2025-08-29 | SELL | -273 | 4.810 | 5.286 | 5.238 | USD -1,430 | 4.86 Loss of -103 on sale |
| 2025-08-27 | BUY | 182 | 5.200 | 5.340 | 5.326 | USD 969 | 4.86 |
| 2025-08-26 | SELL | -91 | 5.160 | 5.320 | 5.304 | USD -483 | 4.86 Loss of -41 on sale |
| 2025-08-25 | BUY | 91 | 5.060 | 5.587 | 5.534 | USD 504 | 4.86 |
| 2025-08-20 | SELL | -360 | 5.330 | 5.510 | 5.492 | USD -1,977 | 4.85 Loss of -232 on sale |
| 2025-08-18 | BUY | 178 | 5.520 | 5.955 | 5.911 | USD 1,052 | 4.84 |
| 2025-08-08 | SELL | -178 | 5.040 | 5.500 | 5.454 | USD -971 | 4.82 Loss of -113 on sale |
| 2025-08-05 | BUY | 88 | 5.610 | 5.950 | 5.916 | USD 521 | 4.81 |
| 2025-08-01 | SELL | -264 | 6.170 | 6.280 | 6.269 | USD -1,655 | 4.79 Loss of -390 on sale |
| 2025-07-30 | BUY | 352 | 6.150 | 6.330 | 6.312 | USD 2,222 | 4.77 |
| 2025-07-18 | BUY | 870 | 6.040 | 6.295 | 6.270 | USD 5,454 | 4.69 |
| 2025-07-17 | SELL | -176 | 6.220 | 6.490 | 6.463 | USD -1,137 | 4.68 Loss of -314 on sale |
| 2025-07-16 | BUY | 3,542 | 6.350 | 6.490 | 6.476 | USD 22,938 | 4.67 |
| 2025-07-11 | SELL | -608 | 6.440 | 6.540 | 6.530 | USD -3,970 | 4.63 Loss of -1,158 on sale |
| 2025-07-07 | BUY | 231 | 5.730 | 5.840 | 5.829 | USD 1,346 | 4.58 |
| 2025-07-02 | BUY | 4,180 | 5.690 | 6.045 | 6.010 | USD 25,120 | 4.55 |
| 2025-06-25 | BUY | 152 | 5.800 | 6.100 | 6.070 | USD 923 | 4.51 |
| 2025-06-11 | BUY | 152 | 5.240 | 5.380 | 5.366 | USD 816 | 4.42 |
| 2025-06-10 | BUY | 152 | 5.150 | 5.650 | 5.600 | USD 851 | 4.41 |
| 2025-06-04 | SELL | -76 | 5.500 | 5.625 | 5.613 | USD -427 | 4.37 Loss of -94 on sale |
| 2025-04-23 | BUY | 76 | 3.320 | 3.400 | 3.392 | USD 258 | 4.38 |
| 2025-04-10 | SELL | -608 | 2.190 | 2.273 | 2.265 | USD -1,377 | 4.58  Profit of 1,410 on sale |
| 2025-04-08 | SELL | -76 | 2.300 | 2.900 | 2.840 | USD -216 | 4.66 Profit of 138 on sale |
| 2025-04-07 | SELL | -76 | 2.380 | 2.910 | 2.857 | USD -217 | 4.69 Profit of 140 on sale |
| 2025-04-04 | SELL | -380 | 2.610 | 2.740 | 2.727 | USD -1,036 | 4.73 Profit of 760 on sale |
| 2025-04-01 | BUY | 304 | 2.420 | 2.900 | 2.852 | USD 867 | 4.80 |
| 2025-03-31 | SELL | -228 | 2.820 | 3.580 | 3.504 | USD -799 | 4.83 Profit of 302 on sale |
| 2025-03-14 | SELL | -1,216 | 3.910 | 4.240 | 4.207 | USD -5,116 | 5.10 Profit of 1,084 on sale |
| 2025-03-07 | SELL | -152 | 4.850 | 4.880 | 4.877 | USD -741 | 5.18 Profit of 46 on sale |
| 2025-03-04 | SELL | -76 | 4.480 | 4.630 | 4.615 | USD -351 | 5.22 Profit of 46 on sale |
| 2025-02-25 | BUY | 152 | 4.690 | 4.925 | 4.902 | USD 745 | 5.31 |
| 2025-02-19 | SELL | -76 | 5.000 | 5.160 | 5.144 | USD -391 | 5.36 Profit of 17 on sale |
| 2025-02-13 | BUY | 228 | 4.500 | 4.530 | 4.527 | USD 1,032 | 5.45 |
| 2025-02-12 | BUY | 76 | 4.110 | 4.290 | 4.272 | USD 325 | 5.50 |
| 2025-02-11 | BUY | 304 | 4.160 | 4.716 | 4.660 | USD 1,417 | 5.55 |
| 2025-01-17 | BUY | 304 | 5.120 | 5.600 | 5.552 | USD 1,688 | 5.96 |
| 2025-01-16 | BUY | 304 | 5.030 | 5.300 | 5.273 | USD 1,603 | 6.10 |
| 2025-01-10 | SELL | -152 | 5.990 | 6.440 | 6.395 | USD -972 | 6.62 Profit of 35 on sale |
| 2025-01-08 | SELL | -304 | 6.340 | 7.080 | 7.006 | USD -2,130 | 7.19 Profit of 56 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of SLN
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 11,472 | 0 | 16,772 | 68.4% |
| 2025-09-18 | 12,177 | 0 | 24,174 | 50.4% |
| 2025-09-17 | 22,042 | 0 | 44,058 | 50.0% |
| 2025-09-16 | 19,220 | 0 | 35,437 | 54.2% |
| 2025-09-15 | 15,383 | 0 | 29,279 | 52.5% |
| 2025-09-12 | 25,602 | 0 | 58,994 | 43.4% |
| 2025-09-11 | 21,900 | 0 | 47,017 | 46.6% |
| 2025-09-10 | 6,805 | 0 | 30,869 | 22.0% |
| 2025-09-09 | 1,947 | 0 | 8,747 | 22.3% |
| 2025-09-08 | 17,254 | 0 | 53,983 | 32.0% |
| 2025-09-05 | 11,808 | 0 | 30,437 | 38.8% |
| 2025-09-04 | 4,538 | 100 | 21,980 | 20.6% |
| 2025-09-03 | 3,995 | 0 | 8,860 | 45.1% |
| 2025-09-02 | 2,235 | 0 | 11,515 | 19.4% |
| 2025-08-29 | 4,333 | 0 | 12,018 | 36.1% |
| 2025-08-28 | 3,650 | 0 | 7,646 | 47.7% |
| 2025-08-27 | 4,288 | 0 | 10,281 | 41.7% |
| 2025-08-26 | 4,981 | 0 | 6,498 | 76.7% |
| 2025-08-25 | 7,315 | 0 | 20,497 | 35.7% |
| 2025-08-22 | 10,328 | 0 | 14,808 | 69.7% |
| 2025-08-21 | 3,680 | 0 | 9,871 | 37.3% |
| 2025-08-20 | 4,646 | 0 | 16,136 | 28.8% |
| 2025-08-19 | 9,199 | 0 | 19,889 | 46.3% |
| 2025-08-18 | 10,868 | 0 | 29,699 | 36.6% |
| 2025-08-15 | 11,583 | 0 | 41,313 | 28.0% |
| 2025-08-14 | 11,730 | 124 | 19,246 | 60.9% |
| 2025-08-13 | 25,362 | 0 | 42,691 | 59.4% |
| 2025-08-12 | 30,355 | 2,754 | 48,290 | 62.9% |
| 2025-08-11 | 27,787 | 561 | 63,361 | 43.9% |
| 2025-08-08 | 14,351 | 1,400 | 38,082 | 37.7% |
| 2025-08-07 | 36,630 | 0 | 72,960 | 50.2% |
| 2025-08-06 | 10,611 | 0 | 28,331 | 37.5% |
| 2025-08-05 | 17,005 | 823 | 31,309 | 54.3% |
| 2025-08-04 | 14,927 | 0 | 34,374 | 43.4% |
| 2025-08-01 | 17,884 | 0 | 30,592 | 58.5% |
| 2025-07-31 | 11,263 | 0 | 20,813 | 54.1% |
| 2025-07-30 | 15,942 | 0 | 30,088 | 53.0% |
| 2025-07-29 | 10,743 | 0 | 44,703 | 24.0% |
| 2025-07-28 | 16,028 | 0 | 29,440 | 54.4% |
| 2025-07-25 | 9,013 | 0 | 20,628 | 43.7% |
| 2025-07-24 | 11,683 | 0 | 22,495 | 51.9% |
| 2025-07-23 | 30,361 | 0 | 65,573 | 46.3% |
| 2025-07-22 | 4,968 | 0 | 28,113 | 17.7% |
| 2025-07-21 | 25,020 | 0 | 47,278 | 52.9% |
| 2025-07-18 | 7,715 | 45 | 27,242 | 28.3% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy